Every November, prostate cancer is the focus of attention for health care providers and patients. It is a disease that affects 1 in 10 men, especially later in life. For example, this disease can already occur in men as young as 50 years. As specialists in medical imaging, we contribute to the detection and removal of prostate cancer. Therefore, we pay special attention to this topic this month.
Early detection is key
Approximately 2,500 men in the Netherlands die from prostate cancer every year. The importance of early detection cannot be overemphasized, as prostate cancer usually shows no symptoms in the early stages and is often only noticed at an advanced stage. By then, treatment is often made difficult, and quality of life can be severely compromised.
Movember
In November, men aged 50 and older are widely encouraged to become aware of the risk of prostate cancer. November is also known as "Movember," a month when men grow their mustaches as an action to draw attention to prostate cancer. The goal is to encourage men to get checked early, so that any diagnosis and treatment can take place in time.
PI Medical as official distributor of Isotopia Molecular Imaging
PI Medical is pleased to announce that as of today we are the official distributor of Isotopia Molecular Imaging for Lu-177 Chloride n.c.a. in the Netherlands and Belgium. Lutetium-177 (Lu-177) is increasingly being used as a promising radionuclide for targeted therapy and has been proven effective in the treatment of prostate cancer, among other things. Clinical studies have shown that Lu-177 treatments can improve the quality of life and progression-free survival of patients with this illness.
A collaboration for a better future
Together with Isotopia Molecular Imaging we look forward to stabilizing the supply of Lu-177 to hospitals to help treat prostate cancer.
Together with healthcare providers, patients, and organizations at home and abroad, we remain committed to fighting prostate cancer and improving care for prostate cancer patients.
